What the study found
The study found that TIMP-HDL-Nano@siPGRN&QT, a matrix metalloproteinase 9 (MMP9)-responsive high-density lipoprotein nanoparticle carrying siRNA against progranulin (siPGRN) and quercetin, reduced renal fibrosis in a mouse model. The authors report that it also improved kidney injury and apoptosis compared with free drug.
Why the authors say this matters
The authors conclude that this nanoplatform enables targeted delivery of RNA and small-molecule therapy to fibrotic kidneys. They suggest it offers a mechanistically defined strategy for renal fibrosis and may have translational potential for other inflammation-driven fibrotic diseases.
What the researchers tested
The researchers designed TIMP-HDL-Nano@siPGRN&QT nanoparticles to co-deliver siPGRN and quercetin. They tested the particles in vitro and in vivo, including in unilateral ureteral obstruction (UUO)-induced renal fibrosis, and used transcriptomic and mechanistic analyses to study how the treatment worked.
What worked and what didn't
The nanoparticles were reported to be about 100 nm in size, with high encapsulation efficiency, good stability, and favorable biocompatibility. The MMP9-responsive modification increased renal accumulation and fibrotic lesion targeting in vivo, and treatment markedly alleviated UUO-induced renal injury, apoptosis, and fibrosis, outperforming free drug. The study also reported reduced pro-inflammatory M1 macrophage polarization and increased M2 polarization in a PPARα-dependent manner.
What to keep in mind
The abstract does not describe detailed study limitations. The findings are reported from a UUO renal fibrosis model, so the summary does not provide information about performance in other models or in humans.
Key points
- TIMP-HDL-Nano@siPGRN&QT combined siPGRN and quercetin in an MMP9-responsive high-density lipoprotein nanoparticle.
- The nanoparticles were about 100 nm in size and were described as stable, efficiently loaded, and biocompatible.
- MMP9-responsive modification increased kidney accumulation and targeting of fibrotic lesions in vivo.
- Treatment reduced UUO-induced renal injury, apoptosis, and fibrosis and outperformed free drug.
- Mechanistic analyses linked the effects to the PGRN-PPARα-NF-κB axis and changes in macrophage polarization.
Disclosure
- Research title:
- MMP9-responsive HDL nanoparticles reduced renal fibrosis in mice
- Authors:
- Weichao Tu, Hao Yan, Yikun He, Yang Zhao
- Institutions:
- Fudan University, Ruijin Hospital, Ruijin Hospital, Shanghai Jiao Tong University, Shanghai University of Traditional Chinese Medicine, Shuguang Hospital, Zhongshan Hospital
- Publication date:
- 2026-07-03
- OpenAlex record:
- View
Get the weekly research newsletter
Stay current with scholarly research without reading academic papers — one filtered digest, every Friday.